Patents by Inventor Thaddeus WADAS

Thaddeus WADAS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Radiotherapeutic and companion imaging agents to target MC1R
    Patent number: 12508329
    Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.
    Type: Grant
    Filed: July 6, 2022
    Date of Patent: December 30, 2025
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., MODULATION THERAPEUTICS, INC., WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventors: David Morse, Robert Gillies, Mark Mclaughlin, Thaddeus Wadas, Hyun Joo Kil, Narges Tafreshi
  • TARGETED ALPHA PARTICLE THERAPY FOR SOMATOSTATIN RECEPTOR 2 POSITIVE NEUROENDOCRINE TUMORS AND METASTASES
    Publication number: 20240207458
    Abstract: Disclosed are TATE derivatives having a linker between the TATE moiety and a macrocyclic radionuclide chelating moiety. Methods of synthesis and use are also disclosed. The compounds preferably exhibit a ratio of kidney: liver uptake by a subject within 24 hours of 5 or less, 3 or less, 1 or less, 0.5 or less, preferably from 2:1 to 1:2.
    Type: Application
    Filed: April 26, 2022
    Publication date: June 27, 2024
    Inventors: David MORSE, Haitao JI, Thaddeus WADAS, Darpan PANDYA
  • RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R
    Publication number: 20230211022
    Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.
    Type: Application
    Filed: July 6, 2022
    Publication date: July 6, 2023
    Inventors: David MORSE, Robert GILLIES, Mark MCLAUGHLIN, Thaddeus WADAS, Hyun Joo KIL, Narges TAFRESHI
  • Radiotherapeutic and companion imaging agents to target MC1R
    Patent number: 11406723
    Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: August 9, 2022
    Inventors: David Morse, Robert Gillies, Mark Mclaughlin, Thaddeus Wadas, Hyun Joo Kil, Narges Tafreshi
  • RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R
    Publication number: 20200108159
    Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.
    Type: Application
    Filed: September 18, 2019
    Publication date: April 9, 2020
    Inventors: David MORSE, Robert GILLIES, Mark MCLAUGHLIN, Thaddeus WADAS, Hyun Joo KIL, Narges TAFRESHI
  • RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R
    Publication number: 20180126013
    Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.
    Type: Application
    Filed: May 6, 2016
    Publication date: May 10, 2018
    Inventors: David MORSE, Robert GILLIES, Mark MCLAUGHLIN, Thaddeus WADAS, Hyun Joo KIL, Narges TAFRESHI